Table 1 Classification of therapeutic agents
Pharmaceutical (generic) | Class | Type | Main mechanism | # Patients |
|---|---|---|---|---|
Ledertrexate (methotrexate) | IS | Antifolate | DNA synthesis inhibition | 34 |
Imuran (azathioprine) | IS | Purine analogue | DNA synthesis inhibition | 24 |
Sulfasalazine (salazopyrine) | IS | Aminosalicylate | Inconclusivea | 9 |
Plaquenil (hydrochloroquine) | IS | TLR blocker | TLR singalling inhibition | 8 |
Arava (leflunomide) | IS | DHODH inhibitor | DNA synthesis inhibition | 3 |
Neoral (cyclosporin) | IS | CNI | Inhibition of T-lymphocyte signaling | 2 |
Advagraf (tacrolimus) | IS | CNI | Inhibition of T-lymphocyte signalling | 2 |
Allochrysine (aurothiopropanolsulfonate) | IS | Gold containing Compound | Inhibition of reduction/oxidation (redox) enzymes | 2 |
Esbriet (pirfenidone) | IS | Small molecule | Broad antifibrotic and anti-inflammatory activities | 1 |
Mercaptopurine (purinethol) | IS | Purine analogue | Inhibits purine nucleotide synthesis | 1 |
Remicade (infliximab) | IM | Monoclonal antibody | Anti-TNFα | 14 |
Humira (adalimumab) | IM | Monoclonal antibody | Anti-TNFα | 9 |
Enbrel (etanercept) | IM | Monoclonal antibody | Anti-TNFα | 4 |
anti-TNFα, not specified | IM | Monoclonal antibody | Anti-TNFα | 2 |
Roactemra (tocilizumab) | IM | Monoclonal antibody | Anti-IL6R | 2 |
Ilaris (canakinumab) | IM | Monoclonal antibody | Anti-IL1β | 2 |
Entyvio (vedolizumab) | IM | Monoclonal antibody | Anti-integrin α4/β7 | 1 |
Kineret (anakinra) | IM | Recombinant RA | Anti-IL1R | 1 |
Stelara (ustekinumab) | IM | Monoclonal antibody | Anti-IL12 and anti-IL23 | 1 |
Trocade | NA | Collagenase inhibitor | Selective inhibitor of matrix metalloproteinase-1 | 1 |
